Table 3.
Results of the Outcome Analyses after Propensity Score Matching.
| Carbazochrome sodium sulfonate (n=14,379) | Control (n=14,379) | Odds Ratio (95% CI) | p value | |
|---|---|---|---|---|
| In-hospital mortality, n (%) | 88 (0.6) | 91 (0.5) | 0.96 (0.72-1.29) | 0.82 |
| Blood transfusion within 7 days of admission | ||||
| Red blood cell transfusion, n (%) | 4,705 (32.7) | 4,591 (31.9) | 1.02 (0.98-1.07) | 0.15 |
| Fresh-frozen plasma transfusion, n (%) | 180 (1.2) | 176 (1.2) | 0.99 (0.76-1.29) | 0.83 |
| Platelet concentrate transfusion, n (%) | 41 (0.3) | 33 (0.2) | 1.28 (0.75-2.20) | 0.35 |
| Carbazochrome sodium sulfonate (n=14,379) | Control (n=14,379) | Absolute Difference (95% CI) | p value | |
| Length of stay, days, mean (SD) | 11.4 (10.0) | 11.0 (10.2) | 0.44 (0.14-0.73) | <0.001 |
| Total Costs, Japanese Yen, mean (SD) | 495,512 (406,516) | 493,696 (437,940) | 1,816 (-10,145-13,777) | 0.72 |
CI: confidence interval, n: number, SD: standard deviation